C07D 265/00
Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen
Official title: Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
C07D265/00 (Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen) appears on 3,001 US grants and 2,671 published applications in this corpus.
Search patents in C07D- Granted patents
- 3,001
- Published applications
- 2,671
- Assignees
- 1,318
- Inventors
- 8,594
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 37 | 0 |
| 1977 | 43 | 0 |
| 1978 | 49 | 0 |
| 1979 | 34 | 0 |
| 1980 | 43 | 0 |
| 1981 | 49 | 0 |
| 1982 | 44 | 0 |
| 1983 | 34 | 0 |
| 1984 | 32 | 0 |
| 1985 | 35 | 0 |
| 1986 | 42 | 0 |
| 1987 | 39 | 0 |
| 1988 | 30 | 0 |
| 1989 | 39 | 0 |
| 1990 | 43 | 0 |
| 1991 | 29 | 0 |
| 1992 | 34 | 0 |
| 1993 | 48 | 0 |
| 1994 | 35 | 0 |
| 1995 | 55 | 0 |
| 1996 | 39 | 0 |
| 1997 | 50 | 0 |
| 1998 | 59 | 0 |
| 1999 | 50 | 0 |
| 2000 | 57 | 0 |
| 2001 | 56 | 13 |
| 2002 | 72 | 82 |
| 2003 | 79 | 92 |
| 2004 | 45 | 101 |
| 2005 | 46 | 116 |
| 2006 | 53 | 125 |
| 2007 | 52 | 90 |
| 2008 | 72 | 66 |
| 2009 | 66 | 117 |
| 2010 | 84 | 160 |
| 2011 | 63 | 127 |
| 2012 | 91 | 109 |
| 2013 | 89 | 112 |
| 2014 | 106 | 114 |
| 2015 | 114 | 127 |
| 2016 | 92 | 139 |
| 2017 | 124 | 115 |
| 2018 | 94 | 124 |
| 2019 | 100 | 102 |
| 2020 | 82 | 134 |
| 2021 | 95 | 91 |
| 2022 | 87 | 77 |
| 2023 | 58 | 111 |
| 2024 | 43 | 104 |
| 2025 | 47 | 81 |
| 2026 | 42 | 42 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- P38alpha mitogen-activated protein kinase inhibitors6 Oct 2026US 12,753,184 B2Gen1E Lifesciences Inc.
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Derivatives of substituted morpholines and uses thereof29 Sep 2026US 12,747,218 B2Supernus Pharmaceuticals, Inc.
- Inhibitors and uses thereof22 Sep 2026US 12,740,991 B2Vividion Therapeutics, Inc.
- Amyloid targeting agents and methods of using the same22 Sep 2026US 12,741,949 B2Amydis, Inc.
- Raf-mek protein complex modulators and methods of use thereof1 Oct 2026US 2026/0297105 A1Gandeeva Therapeutics, Inc.
- Bulky and small-steric-hindrance ligand and use thereof17 Sep 2026US 2026/0273518 A1Dg Hc Optical Co., Ltd
- Herbicidal composition and method for controlling weeds3 Sep 2026US 2026/0256143 A1Enko Chem, Inc.
- Ferroptosis inhibitors and uses thereof27 Aug 2026US 2026/0248800 A1
- Compounds for positive modulation of the autophagy-lysosomal pathway and methods of use27 Aug 2026US 2026/0250256 A1
Most cited
By later US patents
- 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators251US 7,247,625 B2Wyeth · 2007
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Intermediates useful for making 2,4-pyrimidinediamine compounds192US 7,060,827 B2Rigel Pharmaceuticals, Inc. · 2006